Top

BMC Neurology

Published in:

Open Access 01-12-2019 | Ultrasound | Research article

In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA

Authors: Tobias Frühwald, Ulrich Gärtner, Nils Stöckmann, Jan-Henning Marxsen, Carolin Gramsch, Florian C. Roessler

Published in: BMC Neurology | Issue 1/2019

Abstract

Background

Optimizing thrombolytic therapy is vital for improving stroke outcomes. We aimed to develop standardized thrombolysis conditions to evaluate the efficacy of tenecteplase (TNK) compared to the current gold standard rt-PA (alteplase), with and without additional ultrasound treatment. We also wanted to introduce a new analytical approach to quantify fibrin fiber density in transmission electron microscopy (TEM).

Methods

In vitro clots that are similar to ex vivo clots concerning their histological condition and their durability were generated from whole blood. For five treatment groups we compared relative clot weight loss (each n = 60) and fibrin fiber density in TEM (each n = 5). The control group (A) was treated only with plasma. Two groups were designated for each rt-PA (B + C) and TNK (D + E). Groups C and E were additionally treated with ultrasound. Dosages were 50 μg/ml for rt-PA and 30 μg/ml for TNK. Results were evaluated by using analyses of variance (ANOVA) and post-hoc t-tests.

Results

Weight loss was increased significantly for all groups compared to the control group. Both TNK groups showed significantly increased weight loss compared to their counterpart rt-PA group (p ≤ 0.001). For TEM only group D showed significantly decreased fibrin fiber density (p < 0.05) compared to both rt-PA groups. Ultrasound did not significantly increase dissolution of clots with either method (best p = 0.16).

Conclusions

Tenecteplase dissolved clots more effectively than rt-PA with and without ultrasound. A higher sample size could provide more convincing results for TEM.

Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018; https://doi.org/10.1161/CIR.0000000000000558.

Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke. Stroke. 2005. https://doi.org/10.1161/01.STR.0000171066.25248.1d.CrossRef

Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008. https://doi.org/10.1056/NEJMoa0804656.CrossRef

Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, et al. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke. 2012. https://doi.org/10.1111/j.1747-4949.2011.00730.x.CrossRef

Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Utilization of intravenous thrombolysisis increasing in the United States. Int J Stroke. 2013. https://doi.org/10.1111/j.1747-4949.2012.00844.x.CrossRef

Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;2018. https://doi.org/10.1161/STR.0000000000000158.

Campbell BCV, Mitchell PJ, Churilov L, Yassi N, Kleinig TJ et. al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018; https://doi.org/10.1056/NEJMoa1716405.CrossRef

Logallo N, Kvistad CE, Thomassen L. Therapeutic potential of tenecteplase in the management of acute ischemic stroke. CNS Drugs. 2015. https://doi.org/10.1007/s40263-015-0280-9.CrossRef

Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002. https://doi.org/10.2165/00003088-200241150-00001.CrossRef

10.

Bell WR. Present-day thrombolytic therapy: therapeutic agents-pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3:S34–44.PubMed

11.

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012. https://doi.org/10.1056/NEJMoa1109842.CrossRef

12.

Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG et al.; Tenecteplase in Stroke Investigators Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010; https://doi.org/10.1161/STROKEAHA.109.572040.CrossRef

13.

Huang X, Cheripelli BK, Lloyd SM, Kalladka D, Moreton FC, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015. https://doi.org/10.1016/S1474-4422(15)70017-7.CrossRef

14.

Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase3, randomised, open-label, blinded endpoint trial. Lancet Neurol. 2017. https://doi.org/10.1016/S1474-4422(17)30253-3.CrossRef

15.

Coutts SB, Berge E, Campbell BC, Muir KW, Parsons MW. Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials. Int J Stroke. 2018. https://doi.org/10.1177/1747493018790024.CrossRef

16.

Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004. https://doi.org/10.1056/NEJMoa041175.CrossRef

17.

Eggers J, König IR, Koch B, Händler G, Seidel G. Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study. Stroke. 2008. https://doi.org/10.1161/STROKEAHA.107.503870.CrossRef

18.

Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro. Thromb Haemost. 1999;81(4):605–12.CrossRef

19.

Meairs S, Alonso A, Hennerici MG. Progress in sonothrombolysis for the treatment of stroke. Stroke. 2012. https://doi.org/10.1161/STROKEAHA.111.636332.CrossRef

20.

Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke. 2005. https://doi.org/10.1161/01.STR.0000170707.86793.1a.CrossRef

21.

Roessler FC, Teichert A, Ohlrich M, Marxsen JH, Stellmacher F, et al. Development of a new clot formation protocol for standardized in vitro investigations of sonothrombolysis. J Neurosci Methods. 2014. https://doi.org/10.1016/j.jneumeth.2014.08.025.CrossRef

22.

Roessler FC, Wang Z, Schumacher S, Ohlrich M, Kaps M, et al. In vitro examination of the thrombolytic efficacy of desmoteplase and therapeutic ultrasound compared with rt-PA. Ultrasound Med Biol. 2015. https://doi.org/10.1016/j.ultrasmedbio.2015.07.007.CrossRef

23.

Roessler FC, Schumacher S, Sprenger A, Gärtner U, Al-Khaled M, et al. Clot formation in the presence of acetylsalicylic acid leads to increased lysis rates regardless of the chosen thrombolysis strategy. J Vasc Res. 2016. https://doi.org/10.1159/000449386.CrossRef

24.

Holland CK, Vaidya SS, Datta S, Coussios CC, Shaw GJ. Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model. Thromb Res. 2008. https://doi.org/10.1016/j.thromres.2007.07.006.CrossRef

25.

Haley EC Jr, Lyden PD, Johnston KC, Hemmen TM; TNK in Stroke Investigators. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke. 2005; https://doi.org/10.1161/01.STR.0000154872.73240.e9.CrossRef

26.

Tanswell P, Tebbe U, Neuhaus K-L, Gläsle-Schwarz L, Wojcik J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. IACC. 1992;19(5):1071–5.

27.

Eggers J, Ossadnik S, Seidel G. Enhanced clot dissolution in vitro by 1.8-MHz pulsed ultrasound. Ultrasound Med Biol. 2009; https://doi.org/10.1016/j.ultrasmedbio.2008.09.009.CrossRef

28.

Hitchcock KE, Ivancevich NM, Haworth KJ, Caudell Stamper DN, Vela DC, et al. Ultrasound-enhanced rt-PA thrombolysis in an ex vivo porcine carotid artery model. Ultrasound Med Biol. 2011;37(8):1240–51.CrossRef

29.

Barlinn K, Tsivgoulis G, Barreto AD, Alleman J, Molina CA, et al. Outcomes following sonothrombolysis in severe acute ischemic stroke: subgroup analysis of the CLOTBUST trial. Int J Stroke. 2014. https://doi.org/10.1111/ijs.12340.CrossRef

30.

Ricci S, Dinia L, Del Sette M, Anzola P, Mazzoli T, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD008348.pub3.

31.

Saqqur M, Tsivgoulis G, Nicoli F, Skoloudik D, Sharma VK, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies. J Neuroimaging. 2014. https://doi.org/10.1111/jon.12026.CrossRef

32.

Alexandrov AV, Köhrmann M, Soinne L, Tsivgoulis G, Barreto AD, et al. CLOTBUST-ER trial investigators. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Neurol. 2019;18(4):338–47. https://doi.org/10.1016/S1474-4422(19)30026-2.CrossRefPubMed

33.

Papadopoulos N, Damianou C. In vitro evaluation of focused ultrasound-enhanced TNK-tissue plasminogen activator-mediated thrombolysis. J Stroke Cerebrovasc Dis. 2016. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.03.051.CrossRef

34.

Roessler FC, Ohlrich M, Marxsen JH, Stellmacher F, Sprenger A, et al. The platelet-rich plasma clot: a standardized in-vitro clot formation protocol for investigations of sonothrombolysis under physiological flows. Blood Coagul Fibrinolysis. 2011. https://doi.org/10.1097/MBC.0b013e3283468a60.CrossRef

35.

Braaten JV, Goss RA, Francis CW. Ultrasound reversibly disaggregates fibrin fibers. ThrombHaemost. 1997;78(3):1063–8.

36.

Masomi-Bornwasser J, Winter P, Müller-Werkmeister H, Strand S, König J et al. Combination of ultrasound and rtPA enhances fibrinolysis in an in vitro clot system. PLoS One 2017; https://doi.org/10.1371/journal.pone.0188131. eCollection 2017.CrossRef

37.

Francis CW, Blinc A, Lee S, Cox C. Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. Ultrasound Med Biol. 1995;21(3):419–24.CrossRef

38.

Auboire L, Tranquart F, Ossant F, Sennoga C, Bouakaz A. Impact of sonothrombolysis on in vitro blood clot: pictographic validation with electron microscopy. Ultraschall Med. 2017. https://doi.org/10.1055/s-0035-1553322.CrossRef

39.

Petit B, Bohren Y, Gaud E, Bussat P, Arditi M, et al. Sonothrombolysis: the contribution of stable and inertial cavitation to clot lysis. Ultrasound Med Biol. 2015. https://doi.org/10.1016/j.ultrasmedbio.2014.12.007.CrossRef

40.

Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011. https://doi.org/10.1038/nm.2399.CrossRef

41.

De Meyer SF, Denorme F, Langhauser F, Geuss E, Fluri F, et al. Thromboinflammation in stroke brain damage. Stroke. 2016. https://doi.org/10.1161/STROKEAHA.115.011238.CrossRef

42.

Anrather J, Iadecola C. Inflammation and stroke: an overview. Neurotherapeutics. 2016. https://doi.org/10.1007/s13311-016-0483-x.CrossRef

Title: In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA
Authors: Tobias Frühwald
Ulrich Gärtner
Nils Stöckmann
Jan-Henning Marxsen
Carolin Gramsch
Florian C. Roessler
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Ultrasound
Stroke
Tenecteplase
Ultrasound
Published in: BMC Neurology / Issue 1/2019
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-019-1404-5

At a glance: The STEP trials

Springer Medicine

In vitro examination of the thrombolytic efficacy of tenecteplase and therapeutic ultrasound compared to rt-PA

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

ParkProTrain: an individualized, tablet-based physiotherapy training programme aimed at improving quality of life and participation restrictions in PD patients – a study protocol for a quasi-randomized, longitudinal and sequential multi-method study

Irreversible fatal contrast-induced encephalopathy: a case report

A nomogram for predicting the in-hospital mortality after large hemispheric infarction

Spectrum of clinical features and neuroimaging findings in acute cerebral infarction patients with unusual ipsilateral motor impairment– a series of 22 cases

Stent-retriever assisted vacuum-locked extraction (SAVE) versus a direct aspiration first pass technique (ADAPT) for acute stroke: data from the real-world

Selected serum cytokines and nitric oxide as potential multi-marker biosignature panels for Parkinson disease of varying durations: a case-control study